Alnylam Pharmaceuticals raised its 2025 revenue forecast after its drug Amvuttra, used for treating hereditary transthyretin amyloidosis, saw rapid sales growth following a label expansion. Second-quarter revenue nearly doubled year-over-year, beating analyst expectations. The newly approved indication for a rare heart disease (ATTR-CM) helped drive uptake. Alnylam’s optimistic guidance reflects increased market penetration and sets a strong precedent for revenue growth in rare disease therapies.